Post Tagged with: "Amgen"

Amgen Pipeline Remains the Focus Following Soft Quarter

Amgen Pipeline Remains the Focus Following Soft Quarter

April 24, 2014 at 6:15 am

After the markets closed on Tuesday, April 22, Amgen reported a first-quarter adjusted EPS of $1.87, below our estimate of $1.95 and Street’s estimate of $1.93. First-quarter revenue was $4.5 billion, below our estimate of $4.8 billion. Exhibit 1, on the following page, provides a complete variance analysis of theRead More

Biotechs Gain As Barron’s Identifies Opportunities Following Sell-Off

April 17, 2014 at 3:30 pm

Biotech stocks (SPSIBI) are higher Monday following a Barron’s article suggesting selected shares look attractive following a 27% selloff in the sector from February highs of near $4,400. Mentioned in the article are Amgen (AMGN), up 2.1% at $114.29 per share, Gilead Sciences (GILD) up 1.6% at $67.09, and CelgeneRead More